Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease Prophylaxis After Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Trial Profile

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease Prophylaxis After Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2014

At a glance

  • Drugs Bortezomib (Primary) ; Sirolimus (Primary) ; Mycophenolate mofetil
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2014 An additional treatment arm has been added.
    • 21 Jan 2014 Status changed from active, no longer recruiting to discontinued as reported by the ClinicalTrials.gov record.
    • 23 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top